Helena Pópulo
Name: Helena Pópulo
E-mail: hpopulo@ipatimup.pt
Academic Degree: PhD

Helena Pópulo
Helena Pópulo
Member of
Junior Researcher of Cancer Signalling & Metabolism

Short CV


Supervisor of
Luísa Gonçalves, MSc student

PI (running)

PI (closed)
First Author
1. Pópulo H, Nunes B, Sampaio C, Batista R, Pinto MT, Gaspar TB, Miranda-Alves L, Cai RZ, Zhang XY, Schally AV, Sobrinho-Simões M, Soares P
2. Pópulo H, Batista R, Sampaio C, Pardal J, Lopes JM, Soares P
3. Pópulo H, Caldas R, Lopes JM, Pardal J, Máximo V, Soares P
RE: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. Journal of the National Cancer Institute 107: 1, 2015. [Letter] 
 doi: 10.1093/jnci/djv049 PMID: 25755155.
5. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, Pardal J, Azevedo F, Honavar M, Guimarães I, Manuel Lopes J, Sobrinho-Simões M, Soares P
TERT Promoter Mutations in Skin Cancer: The Effects of Sun Exposure and X-Irradiation. The Journal of investigative dermatology 134: 2251-7, 2014. [Article] 
6. Pópulo H, Tavares S, Faustino A, Nunes JB, Lopes JM, Soares P
 doi: 10.7717/peerj.104 PMID: 23904987.
The mTOR Signalling Pathway in Human Cancer. International journal of molecular sciences 13: 1886-918, 2012. [Review] 
Insights into melanoma: targeting the mTOR pathway for therapeutics. Expert opinion on therapeutic targets 16: 689-705, 2012. [Review] 
Analysis of GNAQ mutations, proliferation and MAPK pathway activation in uveal melanomas. The British journal of ophthalmology 95: 715-9, 2011. [Article] 
10. Pópulo H, Soares P, Faustino A, Rocha AS, Silva P, Azevedo F, Lopes JM
mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment cell & melanoma research 24: 254-7, 2011. [Letter] 
11. Pópulo H, Soares P, Rocha AS, Silva P, Lopes JM
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma research 20: 107-17, 2010. [Article] 
Senior Author
1. Sampaio C, Domingues B, Soares P, Lopes JM, Populo H
Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment European journal of cancer (Oxford, England : 1990) 138: S23-S23, 2020. [Meeting Abstract] 
2. Domingues B, Lopes JM, Soares P, Pópulo H
Melanoma treatment in review. ImmunoTargets and therapy 7: 35-49, 2018. [Review] 
 doi: 10.2147/ITT.S134842 PMID: 29922629.
Send Email